RxDoctor Payments Data

David Brost, PA

Medical · Great Falls, MTNPI 1699757682

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,031 of the $6,717 with a category attached, or 89.8%. It is spread thinly across 50 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,540, 7.0 times the $364 reported in 2021. Among medical clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,717in general payments, 2019–2025

Across 345 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$612
  • Merck$574
  • Pfizer$468
  • Incyte Corporation$424
  • Johnson & Johnson$414
  • Novartis$403
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$6,03190%
  • Education$68610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,717 in reported general payments places this provider in the 95th percentile of 134 medical providers in Montana.

See all medical providers in Montana

Medicare billing

Part B allowed, 2024
$70,339
Medicare patients
316
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib15$241,049
KisqaliRibociclib Succinate12$189,729
EliquisApixaban45$40,818
Enoxaparin Sodium11$2,469
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen87$2,001
Oxycodone Hcl50$1,534
Potassium Chloride63$1,133
Anastrozole59$900
Gabapentin63$768
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$601
Levothyroxine Sodium58$409
Tamsulosin Hcl14$395
Omeprazole48$284
Hydroxyurea21$244
Letrozole11$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$468$281,86760 claims
NovartisKisqali$403$189,72912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 medical providers in Montana.

Other medical in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →